Fair Value Calculator Fair Value Calculator
EN DE

Ildong Holdings (000230) Fair Value & Analysis

Healthcare · KR · Market cap 81.5B KRW

IH Ildong Holdings 000230 · KO
Price5,810 KRW
Fair Value16,448 KRW
Upside+183.1%
Quality36/100
Watch Ildong Holdings for free, get notified when fair value or trend changes. Watch for free
Evidence: Medium Range 12,336 KRW – 20,560 KRW 📤 Share as image

Fair value as of: Jul 21, 2026

From 26 valuation models · updated today

Fair value updated Jul 21, 2026, revised from 21,286 KRW to 16,448 KRW (−22.7%) since Jun 25, 2026. Share price −14.4% over the past month.

Price vs Fair Value (12 months)

15,660 KRW 5,710 KRW Fair Value 16,448 KRW Jun 2025 Jul 2026

12‑month range 5,710 KRW – 15,660 KRW · fair‑value band 12,336 KRW – 20,560 KRW · the 5,810 KRW price screens below the 16,448 KRW fair value. As of Jul 21, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Ildong Holdings (000230) currently trades at 5,810 KRW, while our model-based Fair Value estimate is 16,448 KRW, implying the stock looks roughly 183.1% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Ildong Holdings generated revenue of 599B KRW at a net margin of 2.9%. Revenue grew 5.5% year over year. It earns a return on equity of 10.1%. Net debt stands at 117B KRW. Fundamentals as of Jul 21, 2026

Our scenario range runs from 12,336 KRW (bear case) to 20,560 KRW (bull case); at 5,810 KRW, the current price sits below that range. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 183%, 000230 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 599B KRW
Revenue growth (YoY) +5.5%
Net margin 2.9%
Return on equity 10.1%
Free cash flow 9.0B KRW FY2025
Operating margin 6.1%
More key figures
Dividend yield 1.4%
EPS growth (YoY) -62.5%
Net debt 117B KRW FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.

About the company

Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, the company distributes medical devices, quasi drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products through online; and manufactures original and generic prescription drugs. Further, it offers probiotics; pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions; and engages in advertising business. The company was formerly known as …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Ildong Holdings reported revenue of 591B KRW in FY2025 versus 592B KRW in FY2021, a compound −0.1%/yr. Reported net income was 10.9B KRW in FY2025.

Revenue −0.1%/yr
FY21 592B KRW
FY22 676B KRW
FY23 638B KRW
FY24 635B KRW
FY25 591B KRW
Net income
FY21 −70.9B KRW
FY22 −102B KRW
FY23 −59.6B KRW
FY24 63.0B KRW
FY25 10.9B KRW

Is 000230 fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Ildong Holdings Fair Value". https://www.fairvalue-calculator.com/stock/000230

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.36 ¥30.99 -37%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,782 ₹915.92 -49%
Hansoh Pharmaceutical Group 3692 HK$29.58 HK$18.75 -37%
Divi's Laboratories Limited DIVISLAB ₹6,639 ₹1,281 -81%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,421 ₹1,504 -66%
PharmaEssentia Corporation 6446 1,095 TWD 365.87 TWD -67%
Cipla Limited CIPLA ₹1,401 ₹592.37 -58%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,089 ₹841.98 -23%
Lupin Limited LUPIN ₹2,268 ₹2,697 +19%
Mankind Pharma Limited MANKIND ₹2,336 ₹1,068 -54%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Ildong Holdings (000230) undervalued?
As of Jul 21, 2026, our model estimates a fair value of 16,448 KRW versus a price of 5,810 KRW, about +183% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 000230?
Our model-based fair value for Ildong Holdings is 16,448 KRW (as of Jul 21, 2026), built from audited fundamentals. The current price is 5,810 KRW.
What is the quality score of 000230?
Ildong Holdings has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Ildong Holdings (000230)?
Ildong Holdings reported trailing-twelve-month revenue of about 599B KRW (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 000230?
The net profit margin of Ildong Holdings is about 2.9%, meaning it keeps roughly 2.9% of revenue as net income. Based on the latest reported figures.
Does Ildong Holdings pay a dividend?
Ildong Holdings currently shows a dividend yield of about 1.43% relative to its recent price (as of Jul 21, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free alert · no account needed

Tell me when Ildong Holdings reaches its Fair Value

Just your email, and we'll notify you when the price and Fair Value of Ildong Holdings materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.